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Abstract
Background: Hepatitis C virus (HCV) infection is a significant problem among patients undergoing maintenance
hemodialysis (HD). We conducted a prospective multi-center study to evaluate the effect of dialysis machine separation
on the spread of HCV infection.
Methods: Twelve randomly selected dialysis centers in Tehran, Iran were randomly divided into two groups; those using
dedicated machines (D) for HCV infected individuals and those using non-dedicated HD machines (ND). 593 HD cases
including 51 HCV positive (RT-PCR) cases and 542 HCV negative patients were enrolled in this study. The prevalence
of HCV infection in the D group was 10.1% (range: 4.6%– 13.2%) and it was 7.1% (range: 4.2%–16.8%) in the ND group.
During the study conduction 5 new HCV positive cases and 169 new HCV negative cases were added. In the D group,
PCR positive patients were dialyzed on dedicated machines. In the ND group all patients shared the same machines.
Results: In the first follow-up period, the incidence of HCV infection was 1.6% and 4.7% in the D and ND group
respectively (p = 0.05). In the second follow-up period, the incidence of HCV infection was 1.3% in the D group and 5.7%
in the ND group (p < 0.05).
Conclusions: In this study the incidence of HCV in HD patients decreased by the use of dedicated HD machines for
HCV infected patients. Additional studies may help to clarify the role of machine dedication in conjunction with
application of universal precautions in reducing HCV transmission.
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Background
Hepatitis C virus (HCV) transmission occurs mainly
through large or repeated direct percutaneous punctures
to blood vessels; for example repeated injections for drug
abuse [1]. Less frequent routes are sexual transmission [2],
perinatal transmission [3], acquisition from mucous
membrane exposure [4,5], body fluids [6] and colonos-
copy [7]. However, in up to 40% of infected individuals,
the route of transmission remains unknown [8]. Since the
introduction of blood and organ donor screening by anti-
body testing in 1991, HCV has rarely been transmitted by
transfusion of blood products[1], but there remains a rel-
atively high incidence of new infections in hemodialysis
(HD) units [9,10]. Several reports around the world indi-
cate that the frequency of HCV is higher in patients under-
going maintenance HD than in the general population.
The reported prevalence of HCV infection in maintenance
HD patients varies markedly from country to country and
from one center to another [11] ranging between 8% and
39% in North America, 1% and 54% in Europe, 17% and
51% in Asia, and 1% and 10% in Australia [12]. In Iran
the prevalence of HCV varies from 5.5%–24%. [13,15].
Molecular virological studies have clearly shown the
nosocomial transmission of HCV to hemodialysis
patients,[16,17] but the exact modes of transmission
remain unclear. Studies suggest several risk factors, includ-
ing transmission through blood components [18];
patient-to-patient transmission through shared equip-
ment [19], devices [20], or multidose vials [21]; and
between patients treated on the same shift but not sharing
equipment [16]. Basic hygienic precautions, for instance
hand washing, the use of protective gloves when patients
and HD equipment is touched are observed worldwide
but only a few centers have isolated their HCV-positive
patients or dialyzed them during dedicated shift or using
dedicated dialysis machines. At the present time, the
Center for Disease Control and Prevention (CDC) does
not recommend isolation of patients with HCV [1]. The
evaluation of this problem is difficult because of the pau-
city of prospective studies and the scarce data about
patient-to-patient transmission in settings other than HD
centers [6] and therefore the benefit of isolation of HCV
infected dialysis patients remains controversial. The prev-
alence of HCV in hemodialysis units is higher than nor-
mal population in Iran (5–24% [13,15] versus 0.3 [22])
and most other countries. Considering the added expense
of patient isolation we conducted a prospective study in
hemodialysis units in Tehran, Iran, to evaluate the role of
HD machine separation in reducing HCV transmission to
HD patients.
Methods
Among 40 HD centers in Tehran, we randomly selected
centers one by one to reach a total number of 593 patients
(12 centers) to enroll in this study. Selected centers were
randomly divided in to dedicated (D) and non-dedicated
(ND) HD machine groups, including 297 patients in D (4
centers) and 296 patients in ND group (8 centers). ELISA
III checked all patients for HCV antibody detection before
enrolling in the study. Positive cases were confirmed by
RT-PCR. Only patients who were HCV positive by RT-PCR
were considered to be HCV infected. Out of 593 HD cases
51 were RT-PCR positive (30 in the D groups and 21 in the
ND group), and 542 were HCV negative (267 in the D
group and 275 in the ND group). The prevalence of HCV
infection in the D group was 10.1% (range: 4.6%– 13.2%)
and was 7.1% (range: 4.2%–16.8%) in ND group. During
the study conduction, 5 new HCV positive cases (1 in D
group and 4 in ND group) and 169 new HCV negative
cases entered the study. Information regarding age, sex,
occupation (health care personnel, surgeons and den-
tists), HCV infected relatives, previous peritoneal dialysis,
surgery during last 2 months, duration of hemodialysis,
number of blood product transfusions, history of organ
transplantation, and the causes of ESRD was collected.
The obtained history of IV drug abuse, tattooing, and mul-
tiple sex partners was not reliable.
442 patients (254 cases in the D and 192 in the ND
group) were followed for 9 months (first follow up popu-
lation). 281 patients (160 cases in the D and 121 cases in
the ND group) who remained within our study were fol-
lowed for an additional 9 months (Second follow up pop-
ulation). Histories of surgeries or blood product
transfusion were obtained at each follow-up; with no sig-
nificant difference found between the D and the ND
groups. There were no significant differences between the
D and the ND groups in the number of patients lost to fol-
low-up due to death, renal transplantation or transfer to a
different hospital change (data not shown).
Patients were dialyzed for 4 or 4.5 hours, 2 or 3 times
weekly, using standard HD techniques by Cuprophane
and Polysulfone dialyzers. All included HD patients were
HIV and HBs-Ag negative. Dialysis membranes were low-
pressure and used only once and HD machines were
bleached and rinsed between dialysis sessions according
to the manufacturers' instruction. Socioeconomic level
was essentially similar between D and ND groups. The
only difference between two groups of HD centers was
that in-group D, HCV positive patients were assigned to a
dedicated HD machine, but in-group ND, HD HCV posi-
tive and negative patients were not assigned to dedicated
machines. All machines were located in dialysis wards and
not in separate rooms in both groups.
Patient to staff ratio in the D and the ND groups was not
statistically different (3.1 and 3.4 respectively) and all
staff members were negative for anti-HCV. To preventBMC Nephrology 2004, 5:13 http://www.biomedcentral.com/1471-2369/5/13
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HCV transmission, educational courses were held for the
staff to reemphasize the CDC hygienic guidelines; how-
ever, an interview of all nurses directly involved in patient
care disclosed some deviation from CDC hygienic guide-
lines. The minority of nurses remembered situations
when they had failed to change their gloves due to an
urgent adjustment of a hemodialysis machine. A checklist
was used respecting hemodialysis-specific infection con-
trol practices and new gloves were applied for each indi-
vidual patient. Nevertheless, masks, aprons and protective
glasses were not universally used. In all centers, all
patients had specific dialysis stations assigned to them,
and chairs and beds were cleaned after each use. Handling
and storage of medications and hand washing were not
done in the same or adjacent areas to those where used
equipment or blood samples were handled. One of the
ND centers was excluded from the study due to non-
adherence to CDC hygienic guidelines in the first months
of the study.
Statistical analysis was performed using SPSS 10.5 soft-
ware. Comparisons between groups were made by the chi-
square test method for categorical variables and by the t-
test for quantitative variables.
Results
The mean age was 49.5 years (range from 12–84), 58.7%
were male, and the mean HD duration was 21.6 months.
The etiology of end-stage renal disease was hypertension
in 36% followed by diabetes in 28% and glomerulone-
phritis in 10.5%. 15.5% of patients in the dialysis centers
had a one-time history of kidney transplantation, and
2.2% had undergone transplantation twice. The demo-
graphic data for two groups is illustrated in table 1.
In the first follow-up period, the incidence of HCV infec-
tion was 1.6% and 4.7% in the dedicated and the non-
dedicated groups (p = 0.05). In the second follow-up
period, the incidence was 1.3% in the dedicated and 5.7%
in the non-dedicated groups (p < 0.05) (table 2).
Discussion
The possibility of an intradialytic spread of HCV appeared
to be very low and the treatment of HCV infected patients
with dedicated machines was not strictly required [23-26].
Although there is no consensus regarding machine dedi-
cation between HCV non-infected and HCV infected
patients, we found that using dedicated HD machines in
both follow-up periods has an important role in reducing
HCV transmission. Similar results have been shown previ-
ously. Low prevalence of HCV infection (HCV antibodies)
in a HD unit in Istanbul (4.7%) showed that patient iso-
lation and use of dedicated dialysis machines for seropos-
itive patients decrease the transmission of HCV infection
in HD centers [27]. Data derived from another study in
Turkey demonstrated that nosocomial spread of HCV in
HD units in which both seropositive and seronegative
patients were treated together were higher than that of
units with dedicated machines [28]. A study in Lebanon
has shown that infection by HCV may be dialysis
machine-related, rather than transfusion-related [29].
Another study from Portugal also demonstrated that the
incidence of HCV infection was lowest in units that used
dedicated machines or dedicated rooms for anti-HCV-
positive patients [30]. Genotyping analysis in a molecular
study confirmed that implementation of rigorous hygi-
enic routines and introduction of dedicated rooms and
machines for HCV-infected patients are important meas-
ures for effective control of HCV infection in a hemodial-
ysis environment [31]. Findings from a study conducted
Table 1: Demographic characteristics of dedicated and non-dedicated groups.
Cases included at the beginning the study Cases included during the study (new cases)
Dedicated Non-dedicated Dedicated Non-dedicated
Total count of included cases 267 275 85 84
Age [Mean (SE)] 48.5 (0.9) 50.6 (1.0) 47.9(3.1) 51.9(1.8)
Male proportion (%) 59.9 54.2 62.2 61.9
At-risk occupation (%) 0.4* 2.6 5.1 6.1
Duration of HD [Mean (SE)] 24.9(2.8) 25.2 (4.9) 12.6(4.8) 11.8(5.8)
Previous peritoneal dialysis (%) 6.9** 2.2 2.4 2.4
IV drug abuse (%)*** 0.0 1.3 3.9 1.2
Surgery during the last 2 months (%) 1.9 1.5 12.2 8.3
Transfusion during the last 2 months (%) 27.0 21.0 22.0 19.0
Previous transplantation (%) 17.7 18.2 9.5 8.3
* P = 0.04 (Significant difference with the control group)
** P = 0.009 (Significant difference with the control group)
*** History of IV drug abuse was not ascertained.
All other differences between the D and the ND group were not significant.BMC Nephrology 2004, 5:13 http://www.biomedcentral.com/1471-2369/5/13
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in Shiraz, Iran, where 5.5% of patients were anti-HCV pos-
itive indicate that cross-infection by dialysis machines was
mainly responsible for HCV infection. This study also
reemphasized that cross infection through dialysis
machines, rather than transfusion of blood products was
the priming mode of transmission of hepatitis C virus
among HD patients [15].
Some authors recommended that it is sufficient to treat
every dialysis patient as potentially infectious, strictly
adhering to the "universal precautions for prevention of
HCV transmission", to prevent the spread of HCV in dial-
ysis units [32,33] and isolation of HCV-infected dialysis
patients and use of dedicated machines are unjustified
[34]. P. Gilli et al demonstrated that machine separation
in the presence of strict application of hygienic precau-
tions did not reduce HCV transmission [35]. In agreement
to this report, simpler measures such as the observance of
Universal Precautions (UP), continuous training of the
care staff and the use of anti-HCV positive patients per-
sonal instruments which can stop the diffusion of HCV
infection in HD centers [36] have been mentioned.
In our study population, the prevalence of HCV infection
was approximately the same in both groups at the begin-
ning of the study, but significantly lower incidence of
HCV infection in D group may show that machine dedi-
cation strategies can be effective to reduce HCV transmis-
sion at least in our HD centers.
Conclusions
Considering the prevalence of HCV infection and adher-
ence to adequate infection control measures, HD machine
dedication may help to decrease transmission of HCV
infection in our dialysis units.
However rigorous implementation of precaution meas-
ures remains a cornerstone for prevention of HCV trans-
mission among patients undergoing maintenance
hemodialysis, but as unpredictable accidents can always
take place in hemodialysis units; machine dedication may
play a more important role in prevention of HCV trans-
mission. Further studies are needed to evaluate the possi-
ble roles of machine dedication in the presence of strict
adherence to hygienic precautions.
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